Objective: Although estrogen may be linked to biological pathways that maintain higher physical function, the evidence is derived mostly from observational epidemiology and therefore has numerous limitations. We examined whether hormone therapy affected physical function in women 65 to 79 years of age at enrollment.
I mpairments in physical function, such as decreased muscle strength and balance, increase sharply with age. 1 Declines in physical function are associated with increased risk of disability, especially among older women. 2, 3 Prior research suggests that estrogen depletion in women, related to hormonal transitions of menopause, causes physiological changes that damage the musculoskeletal system, thus causing subsequent decreases in function. 4, 5 The mechanisms by which estrogen influences muscle function remain unknown, but studies have established that estrogen and estrogen receptors in the skeletal muscle cells of women 4 regulate carbohydrate and lipid metabolism. Moreover, recent data suggest that higher endogenous estrogen levels and lower sex hormoneY binding globulin concentrations were associated with muscle strength in 75-year-old women. These parameters were associated with lower rates of fall-related limb fractures even after adjusting for bone mineral density. 5 The literature on connections between hormone therapy (HT) and physical function is complex because of inconsistent use of definitions and measurement of physical function, different classifications of HT use, and study design effects. Results from cohort studies examining the role of HT on physical function are not consistent, with some studies reporting improved physical function associated with HT, 6 some reporting decrements, 7 and others reporting no association. 8 In randomized controlled trials (RCTs) examining the effects of HT on physical function, results have also been inconclusive. 9<12 However, these trials relied on self-reported physical function, rather than on objective measures, 9<11 or failed to differentiate between unopposed estrogen and estrogen + progestin. 12 Identification of factors that affect changes in physical function can provide information useful for forecasting disability burden and related outcomes. Furthermore, evidence regarding the association between HT and physical function could inform our understanding of the musculoskeletal impact of hormone depletion associated with the menopausal transition and help physicians counsel women about the effects of HT. This study investigated the association between HT and changes in performance-based measures of physical function as part of the Women's Health Initiative (WHI).
METHODS

Design overview
The WHI includes two randomized, placebo-controlled hormone trials: the estrogen + progestin therapy (EPT) trial in women with intact uteri and the estrogen therapy (ET) trial in women who had undergone prior hysterectomy. Follow-up contacts by telephone or clinic visit occurred every 6 months, with clinic visits required annually. Informed consent was obtained using forms approved by local institutional review boards.
Setting and participants
The eligibility criteria, recruitment procedures, and main study outcomes for the hormone trials have been published previously. 13<15 Briefly, postmenopausal women aged 50 to 79 years were recruited between October 1993 and December 1998 at 40 US clinical centers and randomized to one of the HT trials.
Randomization and interventions
Women who had had a hysterectomy received either placebo or ET (0.625 mg/d conjugated equine estrogens supplied by Wyeth), and women who had not undergone a hysterectomy received either placebo or EPT (0.625 mg/d conjugated equine estrogens plus 2.5 mg/d medroxyprogesterone acetate in a combined tablet; Wyeth). Participants and clinic staff were blinded to the study pill assignments.
Outcomes and follow-up
As part of the WHI's overall goal to identify and prevent major causes of disability, performance-based measures of physical function were taken from a 25% subsample of WHI Clinical Trial participants aged 65 to 79 years. Physical function was measured at baseline and again at 1, 3, and 6 years by trained, certified clinical center staff blinded to treatment group. When obtained under standardized conditions, the performance-based measures of physical function included in the WHI are reliable, have strong predictive validity, and are somewhat sensitive to change. 16<18 Timed-walk and chair-stand tests provided information on gait and dynamic leg strength, respectively. Grip strength is a measure of upper extremity functional status and has been used as a general indicator of frailty. For each measure, the better of two trials was used in the analyses. Extreme and implausible function assessments were excluded from analyses. In the timed-walk test, a stopwatch was used to measure the number of seconds (to the nearest one-tenth second) from start to when the first foot completely crossed the end line of a 6-meter course. Participants used ambulatory aids as needed. Walk pace was calculated as meters per second. The chair-stand test counted the number of times a participant could stand up from a straight-back armless chair without using her arms. Grip strength was measured in the dominant arm using a hand-grip dynamometer (Jamar hand-grip dynamometer). Measurement was recorded to the nearest kilogram (rounding up) for both trials.
Statistical analyses
Primary analyses were performed on an intent-to-treat basis. Baseline characteristics were compared by randomized groups using W 2 tests, or Fisher's exact test when subgroups contained fewer than five women. Analyses of the short-term effects of HT focused on changes in physical function from baseline to year 1 and long-term effects at years 3 and 6. For each of the three performance-based physical function measures, the effects of ET and EPT randomization assignment on physical function change score were assessed separately in linear models. Analyses were conducted in SAS 9.1 (SAS Institute Inc, Cary, NC) using PROC GLM. To account for the correlated structure of performance data across repeated measurements, a mixed-effect model was used to fit the 3and 6-year longitudinal performance data as a function of follow-up time since baseline, using PROC MIXED. 19 The results from the mixed-effect models did not differ from the results from the linear models; thus, we report only the results of the linear models. Sensitivity analyses were conducted to examine the effect of nonadherence by repeating these analyses among women who were at least 80% adherent during follow-up. Additional sensitivity analyses evaluated the potential influence of incident conditions by excluding women who experienced a health outcome that may impair physical performance and is also related to HT (stroke, myocardial infarction, breast cancer, hip or knee replacement, any fracture, and venous thromboembolism) before the follow-up function assessment. To evaluate the influence of stopping HT on function, models were stratified by current HT status.
Unadjusted models were run first, followed by models adjusted for clinic, randomization into the calcium/vitamin D and dietary modification arms of the WHI, and baseline characteristics that significantly differed (P G 0.05) between the intervention and control groups within each treatment arm. Linear modeling assumes complete information (ie, no missing data) for the covariates in an analysis. Because the amount of missing data on each confounding factor was small, participants with missing covariate data were excluded from the adjusted models.
To examine whether there were any important subgroup effects, a series of two-way interaction terms (treatment Â baseline characteristic) were evaluated in the adjusted models.
Twenty-nine interaction terms were added separately to test the interaction significance (see Table 1 for list of baseline characteristics). Because one to two interaction terms at each time point would be significant because of chance alone, a stratified adjusted model was run to evaluate the effect of HT by level of baseline characteristic only if the interaction term was significant (P G 0.05) at two or more time points. Women self-reported their race/ethnicity as American Indian or Alaskan Native; Asian or Pacific Islander; black or African American; Hispanic/Latino; white (not of Hispanic origin); or other. Because of the low frequency of nonwhite selections, race/ethnicity was collapsed into white and nonwhite for this analysis.
Clinical significance
The clinical significance of the results was determined by calculating the effect size and smallest increment of change. Effect size was defined as as large, effect size of 0.80 or greater; medium, 0.50 to 0.79; or small, 0.20 to 0.49. The smallest increment of change was determined using measurements of functional assessments.10 For example, grip-strength measurements were rounded up for a smallest increment of change of 1 kg.
Power
Power was assessed in terms of the study's ability to detect a clinically significant change in function given the available number of observations. Effect size was used as an indicator of clinical significance as described above. Low ends of the ranges were used as cutoffs to not overestimate power. Effect size was calculated in Excel using PROC MEAN output for treatment and control groups. PROC GLMPOWER in SAS 9.1 (SAS Institute Inc) was used to calculate power.
RESULTS
The WHI study population included in these analyses is described in Fig. 1 . A total of 5,310 women were in the ET group and 5,429 women were in the placebo group for the ET trial, whereas 8,506 women were in the EPT group and 8,102 women were in the placebo group in the EPT trial. For the analyses presented here, participants younger than 65 years (n = 15,101) or disabled at baseline (n = 1,721) were excluded. Of the 3,858 women remaining in the ET trial, 922 (23%) women were randomly selected to participate in the physical function subsample and completed all baseline assessments; of the 6,087 women remaining in the EPT trial, 1,458 (24%) were randomly selected to participate in the physical function subsample and completed all baseline assessments (Fig. 1) , for a total of 2,380 women in the subsample. During 6 years of follow-up, 1,365 (57.4%) of the 2,380 women completed physical function assessments at all three time points and 2,289 (96.2%) women completed these assessments at least once during follow-up. After 6 years, participants' grip strength declined by 12.0%, chair-stand ability declined by 3.5%, and walk pace slowed by 11.4% from baseline.
Baseline characteristics among participants in the physical function subsample by treatment arm and randomization status are shown in Table 1 . In the ET arm, baseline grip strength, years since menopause, and experience of hot flashes or night sweats differed between the intervention and control groups. In the EPT arm, there were no significant differences between the control and intervention groups.
Average changes in function assessments by treatment arm are provided graphically in Fig. 2 . The effects of ET and EPT on function change were not significant in short-or long-term models of any functional test (Tables 2 and 3 ). Adjustment for characteristics that differed at baseline did not affect the significance of the effects. Among the most adherent participants in the EPT arm, the chair-stand ability of the intervention group declined by an average of 0.41 more than that of the control group at year 6 (j1.52 vs j1.11 stands, respectively; P = 0.04). Although statistically significant, this difference indicates a small clinical effect. Results were unchanged in models that excluded women with incident conditions and stratified by active intervention status (data not shown).
The association between EPT use and physical function seemed to vary according to race at year 6 (P G 0.01). Among nonwhite women, women randomized to EPT retained 3.60 kg more grip strength than that of women randomized to placebo after 6 years of follow-up (P = 0.04). This difference is clinically significant (D = 1.03). Evaluating the effect on specific racial/ethnic categories (ie, Asian/Pacific Islander, African American, and Hispanic) failed to produce significant results, probably because of the very small sample sizes (26-38 women). There was no evidence that the association between unopposed estrogen and physical function varied by race.
DISCUSSION
Analyses of WHI data from RCTs comparing estrogen alone and estrogen + progestin with placebo in women 65 to 79 years of age at enrollment showed no evidence of treatment effects on measures of physical function. Analyses of women who were highly adherent (Q80%) to the treatment did not alter the primary results. The results remained unchanged after excluding women with incident conditions associated with HT during follow-up. Stopping HT did not result in a change in function in this population. The observed improved grip strength associated with EPT in nonwhite women in this study should be interpreted cautiously given that effect modification by race was not proposed a priori and there is no known mechanism for the observed association. This study did not address the influence of HT for women of younger ages.
The overall results are similar to the results from the only other clinical trial that directly assessed the relation between HT and change in performance-based measures of physical function among older women. 12 That trial also reported no clinically meaningful associations. However, Greenspan et al 12 were not able to differentiate between EPT and ET and did not collect follow-up data after cessation of HT. In a recent trial of EPT and exercise training for 1 year among 51 women aged 50 to 57 years, significant changes were seen in the improving condition of the skeletal muscle and in preventing attenuation in women during the early postmenopausal phase; these changes likely exerted a positive effect on muscle performance. 21 We are unable to examine whether HT produces differential effects depending on when it is administered in relation to the menopausal transition with respect to physical functioning because of the nature of our cohort and because very few women were past users of HT (Table 1) . However, a recent analysis of the WHI randomized HT trials found no evidence of a beneficial effect of initiation of HT close to menopause for a wide variety of health outcomes, including coronary heart disease, total cancer, hip fracture, total mortality, and a summary global index. 22 Randomized trials that assessed the relation between HT and change in self-reported physical function reported conflicting results. The Heart and Estrogen/Progestin Replacement Study reported a significantly faster decline in self-reported physical function scores among 2,763 women assigned to EPT therapy after 3 years. 11 In contrast, the WHI found no association between HT and self-reported physical function after 3 years. 9, 10 Performance-based measures of physical function are generally preferable to self-reported measures because of their high reliability and strong predictive value. 23 The current study excludes participants without function measures at follow-up visits. However, the percentage of participants with incomplete follow-up did not significantly differ between the treatment (41.9%) and control (43.4%) groups (P = 0.48). In general, women with incomplete follow-up were older and had lower physical function at baseline. The difference in age was small (0.4 y) but significant (P G 0.01). Baseline grip strength did not differ by follow-up (P = 0.85), but baseline chair stands and walk pace did (P G 0.0001 for both). Women with incomplete follow-up performed 0.3 fewer chair stands and 0.1 meter/second slower walk pace at baseline compared with women with complete follow-up. Although the population included in these analyses may have been healthier than the general population, follow-up did not differ by treatment/control status and does not explain our null findings. However, if a younger and healthier population is less likely to experience functional decline, this study may have had a decreased ability to detect function change. In addition, most (91.0%) women with incomplete follow-up completed at least one follow-up assessment and were included in the analysis to some extent.
This study had adequate power (Q0.80) to detect very small differences in functional change (difference, Q0.22). In the ET trial, the 6-year analysis had adequate power to assess a difference of 1.31-kg change in grip strength, 0.47 change in chair stands, and 0.07-meter/second change in walk pace (a difference of 0.38 s in the 6-meter timed walk) between the treatment and control groups. The EPT trial had power to detect differences of 1.04 kg, 0.36 stand, and 0.06 meter/second, respectively.
Negative confounding is a possible explanation for finding that follow-up status did not vary by study arm. Significant differences between the EPT group and placebo group in the current study were observed for three measured variables: experience of hot flashes, years since menopause, and baseline grip strength. Although we were able to adjust our analyses for these factors, it is possible that other unmeasured and unknown risk factors for decline in physical function were imbalanced between the study arms. Simulation studies demonstrate that bias in the exposure effect estimate increases as the amount of residual and unmeasured confounding increases. 24 In the current analysis, adjustment for characteristics that differed at baseline did not affect significance of effects, suggesting that the likelihood that unmeasured confounding completely explains the null results of this study was small.
Our finding that, on average, physical function in our study sample declined over time should be interpreted in light of other studies. In a study that followed a population-based sample of 5,178 community-dwelling women for more than 10 years, walking speed decreased by 17% (SD, 24%) and time to complete five chair stands increased by 22% (SD, 44%; both P values G 0.0001). 7 In a study of short-term changes in walking speed, chair-stand ability, and grip strength among 1,002 community-dwelling women with some disability at baseline, Onder et al 3 reported an 11.2% decline in mean chair-stand ability after 1 year (21.1% by year 3), a 1-year decline of 5.2% in mean walking speed (16.2% by year 3), and a 1-year decline of 1% in mean grip strength (6.8% by year 3). In this study, decline in grip strength is comparable with that in the study of Onder et al. Short-term decline in walk pace is comparable, although long-term decline may be slower in the WHI sample. Decline in chair stands was notably slower in the WHI's sample than in the other two studies, in both the long and the short terms. This is consistent with the fact that, in general, RCTs enroll healthier participants than community studies do.
CONCLUSIONS
In conclusion, hormone treatment provided no overall protection against functional decline in nondisabled postmenopausal women 65 years or older in 6 years of follow-up. Possible race differences in the influence of HT on change in function should be explored in future research.
